Journal Information
Vol. 38. Num. 2.March - April 2018
Pages 109-246
Visits
1305
Vol. 38. Num. 2.March - April 2018
Pages 109-246
Original article
DOI: 10.1016/j.nefroe.2017.10.012
Open Access
A new generation of cellulose triacetate suitable for online haemodiafiltration
Una nueva generación de triacetato de celulosa adecuado para hemodiafiltración on-line
Visits
1305
Francisco Maduella,
Corresponding author
fmaduell@clinic.ub.es

Corresponding author.
, Raquel Ojedaa, Marta Arias-Guilléna, Néstor Fontseréa, Manel Veraa, Lida Rodasa, Miquel Gómeza, Karen P. Huablochoa, Fanny Esquivela, Paola D. Moria, Valentina Hoffmanna, Jessica Ugaldea, Nayra Ricob
a Servicio de Nefrología, Hospital Clínic Barcelona, Barcelona, Spain
b Servicio de Bioquímica, Hospital Clínic Barcelona, Barcelona, Spain
This item has received
1305
Visits

Under a Creative Commons license
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (5)
Show moreShow less
Tables (3)
Table 1. In vitro features of the dialysers under study.
Table 2. Comparison of dialysis parameters in the 4 dialyser situations (n=16).
Table 3. Reduction percentage of solutes in haemodialysis and hemodiafiltration.
Show moreShow less
Abstract
Background

Online haemodiafiltration (OL-HDF) is currently the most effective dialysis technique that also improves survival. To date, high permeability membranes with low albumin loss, such as polysulfone, polyamide and polyacrylonitrile membranes have been the most widely used. However, the initially restricted use of cellulose triacetate (CTA) membranes in OL-HDF has expanded. The aim of the study was to ascertain whether the latest generation asymmetric CTA membranes are more effective in obtaining high convective transport.

Patients and methods

A total of 16 patients (10 males and 6 females) undergoing OL-HDF were studied. Each patient underwent 4 different sessions, with haemodialysis or OL-HDF, and/or with CTA or asymmetric CTA 1.9m2 membranes. Each session was assigned in a randomised order. Serum levels of urea, creatinine, β2-microglobulin, myoglobin, prolactin, α1-microglobulin, α1-acid glycoprotein and albumin where measured at the beginning and end of each session to obtain the reduction rate. The loss of solutes and albumin was quantified from the dialysate.

Results

A significantly greater replacement volume in OL-HDF (32.1±3.1 vs. 19.7±4.5 l, p<0.001) was obtained by using asymmetrical CTA membranes compared to conventional CTA membranes. Regarding uraemic toxin removal, both membranes obtained similar results for small molecules, whereas asymmetric CTA membranes achieved better results for large molecules, increasing the reduction ratio by 29% for β2-microglobulin, 27.7% for myoglobin, 19.5% for prolactin, 49% for α1-microglobulin and double for α1-acid glycoprotein (p<0.01 in all situations). The loss of albumin was less than 2g for all treatment sessions.

Conclusion

Latest-generation asymmetric CTA have proven to be effective in attaining OL-HDF objectives without increased albumin loss.

Keywords:
Biocompatibility
Online haemodiafiltration
Cellulose triacetate
Convective volume
Resumen
Antecedentes

La hemodiafiltración on-line (HDF-OL) es actualmente la técnica de hemodiálisis (HD) más efectiva y aumenta la supervivencia. Hasta el momento presente las membranas de alta permeabilidad con baja pérdida de albúmina como las de polisulfona, poliamida y poliacrilonitrilo son las más utilizadas. Las membranas de triacetato de celulosa (TAC), limitadas inicialmente para su uso en HDF-OL, han evolucionado. El objetivo del estudio fue determinar si las membranas de nueva generación de TAC asimétrico (TACA) son más adecuadas para realizar alto transporte convectivo.

Pacientes y métodos

Se estudiaron 16 pacientes, 10 hombres y 6 mujeres, en programa de HDF-OL. A cada paciente se le realizaron 4 sesiones diferentes, con HD o HDF-OL, o con filtros de TAC o TACA de 1,9m2, aleatorizando el orden. En cada sesión se determinaron concentración de urea, creatinina, β2-microglobulina, mioglobina, prolactina, α1-microglobulina, α1-glicoproteína ácida y albúmina en suero al inicio y al final de cada sesión, para calcular el porcentaje de reducción. Así mismo, se cuantificó la pérdida de solutos y albúmina en el líquido de diálisis.

Resultados

Con las membranas de TACA se consiguió un volumen de sustitución en HDF-OL significativamente superior a las membranas de TAC clásicas (32,1±3,1 vs. 19,7±4,5L; p<0,001). En términos de depuración, la eliminación de moléculas pequeñas fue similar con ambas membranas, pero, en moléculas grandes, con HDF-OL la depuración fue mayor con TACA. En HDF-OL, el porcentaje de reducción de la β2-microglobulina se incrementó un 29%, un 27,7% la mioglobina, un 19,5% la prolactina, un 49% la α1-microglobulina, y se duplicó la α1-glicoproteína ácida (p<0,01 en todas las situaciones). La pérdida de albúmina fue inferior a 2g en todas las situaciones de estudio.

Conclusión

Las membranas de TAC de nueva generación han demostrado ser eficaces para alcanzar los objetivos de HDF-OL, sin que haya una mayor pérdida de albúmina.

Palabras clave:
Biocompatibilidad
Hemodiafiltración on-line
Triacetato de celulosa
Volumen convectivo
Full Text
Introduction

The number of patients receiving on-line haemodiafiltration (HDF) has increased in recent years because randomised clinical trial in prevalent patients1 have shown increased survival. Afterwards, various meta-analyses have confirmed a reduction in cardiovascular and overall mortality.2,3 Secondary analyses of studies looking at mortality as the main variable1,4,5 observed an association between convective volume and survival; so a minimum convective volume of 21l per session6 is being recommended. The main limiting factors to achieve high convective volumes are blood flow (Qb), time and the dialyser.

The pharmaceutical industry, in line with the technological advances made in haemodilaysis (HD) monitors, has developed improved dialysers able to achieve greater clearance capacity with a better adaptation to highly convective treatments. In fact, not all dialysers are appropriate to perform this type of treatment.

In a previous study7 of 11 dialysers evaluated for on-line HDF treatment, only cellulose triacetate (CTA) membranes and polymethyl methacrylate (PMMA) demonstrated to be less appropriate for on-line HDF with less β2-microglobulin (β2-m) clearance and limited capability to reach a suitable convective volume with elevated transmembrane pressure. Recently, Potier et al.8 published the use of 19 dialysers for on-line HDF; they observed that in seven of them, albumin loss per session was excessive. Therefore, the use of these dialysers for highly convective techniques is questioned.

Synthetic dialysers made of polysulfone (polyethersulfone, helixone) polyamide and polyacrylonitrile have been used most frequently in the past few years in HD and also in on-line HDF. However, in recent years, intolerance reactions (low blood pressure, desaturation) to synthetic dialysers have been observed in a small percentage of patients.9,10 This is a reason by which cellulose dialysers, such as CTA, have been reintroduced as an alternative to the dialysers previously mentioned. Initial CTA dialysers presented a low ultrafiltration coefficient, and therefore there are limitations of their use for haemodiafiltration. However, a new generation of dialysers with asymmetric CTA membranes have been designed with an increase in hydraulic permeability that deserves attention.

The aim of this study was to evaluate this new generation of asymmetric CTA dialysers (Solacea®), compared with the previous generation of CTA (Sureflux®) in HD and on-line HDF modalities.

Patients and methods

This is an study performed in a single centre including stable HD patients. Sixteen patients were evaluated, 10 men and 6 women, with a mean age of 64.7±12 years (interval of 49–90 years) on regular HD programmes. The aetiology of chronic kidney failure was 5 chronic glomerulonephritis (31.2%), 2 diabetic nephropathies (12.5%), 1 polycystic disease (6.3%), 1 vascular nephropathy (6.3%), 2 urological causes (12.5%), 2 systemic diseases (12.5%), 1 tubular interstitial nephropathy (6.3%) and 2 undetermined aetiologies (12.5%). All patients were dialysed through an arteriovenous fistula.

Patients were dialysed with the 5008 Fresenius monitor, suitable for on-line HDF. Four separate sessions were carried out in each patient with their usual parameters of dialysis (time 290±18min, Qb 462±34ml/min, Qd 500ml/min): 1) HD with 1.9m2 CTA (Sureflux 19 UX, Nipro), 2) on-line HDF with 1.9m2 CTA (Sureflux 19 UX, Nipro), 3) HD with new generation 1.9m2 CTA (Solacea 19H, Nipro) and 4) on-line HDF with new generation 1.9m2 CTA (Solacea 19H, Nipro). The order of the sessions was randomised. Table 1 summarises the characteristics of both dialysers.

Table 1.

In vitro features of the dialysers under study.

  Sureflux 19UX  Solacea 19H 
Membrane  Cellulose triacetate  Asymmetric cellulose triacetate 
Priming volume (ml)  109  108 
KUF (ml/h/mmHg)  41  72 
Wall thickness (μm)  15  25 
Internal diameter (μm)  200  200 
Surface area (m21.9  1.9 
Sterilisation  Gamma radiation  Gamma radiation 
SC β2-microglobulin  0.70  0.85 
SC myoglobin  0.65  0.80 
SC albumin  0.005  0.013 

KUF: ultrafiltration coefficient; SC: sieving coefficient.

Dialysers are automatically primed with the 5008 monitor. On-line HDF was performed with post-dilution infusion using an automatic infusion flow. The dialysis parameters collected in each session were: dialysis time, dialyser, dialysate flow rate (Qd), blood flow (Qb), total blood volume processed, needles, initial weight, final weight, weight gain, Kt automatically measured by ionic dialysance, recirculation index measured by the temperature module, arterial blood pressure, venous blood pressure, transmembrane pressure, initial and final haemoglobin, ultrafiltration and substitution volume.

Concentrations of urea (60Da), creatinine (113Da), β2-m (11,800Da), myoglobin (17,200Da), prolactin (23,000Da), α1-microglobulin (33,000Da) and α1-acid glycoprotein (41,000Da) and serum albumin (66,000Da) at the start (C1) and at the end (C2) of each session were determined in order to calculate the percentage reduction of these solutes (PR=100×(C1C2)/C1). The final concentration of β2-m, myoglobin, prolactin, α1-microglobulin, α1-acid glycoprotein and albumin were corrected for haemoconcentration and volume of distribution (approximately the extracellular volume) according to Bergström and Wehle,11 according to the corrected C2 formula=C2/[1+(weight gain/0.2×final weight)]. Final extraction was done at the end of dialysis and after reducing blood flow to 100ml/min for one minute.

Urea, creatinine and albumin concentrations were measured by molecular absorption spectrometry in the ADVIA 2400 analyser (Chemistry System from Siemens Healthineers, Tarrytown, USA). β2-m and α1-acid glycoprotein were measured by immunonephelometry using the Dimension Vista (Siemens Healthineers) analyser and α1-microglobulin by immunonephelometry using the BNII (Siemens Healthineers) analyser. Myoglobin concentrations were measured by indirect enzyme immunoassay (EIA) with the Dimension EXL (Siemens Healthineers) analyser. Prolactin concentrations were measured by indirect enzyme immunoassay (EIA) with the ADVIA Centaur (Siemens Healthineers) analyser.

Dedicated reagents were used in all cases. Our laboratory's reference values are urea:10–50mg/dl; creatinine: 0.3–1.3mg/dl, β2-m: 0.1–2.3mg/l; myoglobin 0–100ng/ml; prolactin: 2.8–15ng/ml, α1-microglobulin: 5–25mg/l; α1-acid glycoprotein: 0.38–1.18g/l and albumin 34–48g/l.

Likewise, a proportional part of the dialysis fluid was collected to quantify the loss of solutes and albumin. Urea, creatinine and prolactin were measured as in serum. However, because the β2-m and albumin concentrations were very low, they had to be analysed with the same technology, but with determination methods for urine to increase analytical sensitivity. β2-m was measured with an improved detection index, 0.004625mg/l.

The results are expressed as the arithmetic mean±standard deviation. The Students’ t-test was used to analyse the statistical significance of quantitative parameters obtained from paired data, and the ANOVA test was used for repeated data. A p value of <0.05 was considered statistically significant.

Results

We observed a very satisfactory tolerance to these filters. No abnormal reactions were observed to the connection, disconnection, or during the on-line HD or HDF sessions. Coagulation of the lines or the dialyser did not occur in any session. Anticoagulation was low-molecular-weight heparin (tinzaparin) in 62%, heparin sodium in 19%. The remaining sessions (19%) did not include heparin.

There were no differences in dialysis parameters, Qd, Qb, total blood processed by the monitor, needle size, vascular access recirculation, session duration, initial weight, final weight, weight gain, the dialysis monitor's own measurements of initial and final haematocrit, arterial blood pressure, venous blood pressure or transmembrane pressure (Table 2).

Table 2.

Comparison of dialysis parameters in the 4 dialyser situations (n=16).

  Sureflux 19UX HD  Sureflux 19UX HDF  Solacea 19H HD  Solacea 19H HDF  p 
Qd (ml/min)  500  500  500  500  NS 
Prescribed Qb (ml/min)  462±34  462±34  462±34  462±34  NS 
Blood cleared (l)  131.9±14.6  129.6±14.1  131.3±14.3  130.3±14.9  NS 
Needles  15151515NS 
Recirculation (%)  14.5±3.3  13.9±1.4  15.2±2.7  15.1±2.6  NS 
Td prescribed (min)  290±18  290±18  290±18  290±18  NS 
Initial weight (kg)  72.41±17.8  72.29±17.9  72.33±18.0  72.77±17.5  NS 
Final weight (kg)  69.88±17.4  69.79±17.5  69.98±17.7  69.97±17.6  NS 
Weight gain (kg)  2.53±0.83  2.50±0.80  2.34±0.78  2.80±1.21  NS 
Initial haematocrit (%)  29.93±3.89  29.86±3.69  29.98±4.29  29.81±4.13  NS 
Final haematocrit (%)  36.74±4.46  37.28±5.14  37.05±4.32  37.58±5.41  NS 
Arterial blood pressure (mmHg)  −221.6±25  −223.3±29  −212.6±33  −221.5±28  NS 
Venous blood pressure (mmHg)  237.4±27  235.6±31  243.6±31  244.5±26  NS 
TMP (mmHg)  37.1±12  174.1±26a  36.1±6b  181.8±20a,c  Sig. 

Td: dialysis time; NS: not significant; Qb: blood flow; Qd: dialysate flow rate; Sig: significant; TMP: transmembrane pressure.

a

p<0.01 relative to Sureflux-HD.

b

p<0.01 relative to Sureflux-HDF.

c

p<0.01 relative to Solacea-HD.

The post-dilution on-line HDF substitution volume was 19.7±4.5l (ranging between 18 and 34l) with Sureflux 19UX and 32.1±3.1l with Solacea 19H (interval between 26 and 37l), p<0.001 (Fig. 1). This first observation shows that this new CTA generation achieves a much higher substitution volume, and therefore it is suitable for on-line HDF.

Fig. 1.
(0.04MB).

Variations in on-line haemodiafiltration substitution volume by dialyser, n=16, ANOVA for repeated data.

Solute clearance

Effective clearance of solutes expressed as percentage of solute reduction is found in Table 3 and in Figs. 2–4.

Table 3.

Reduction percentage of solutes in haemodialysis and hemodiafiltration.

  Sureflux 19UX HD  Sureflux 19UX HDF (19.7±4.5l)  Solacea 19H HD  Sureflux 19H HDF (32.1±3.1l) 
Urea (60Da)  85.5±3.4  85.7±4.3  83.0±4.9a,b  85.6±3.8c 
Creatinine (113Da)  78.6±4.0  78.0±4.8  76.3±5.0a,b  79.3±4.2c 
β2-Microglobulin (11,818Da)  67.3±5.0  62.4±5.1a  71.5±6.7a,b  80.4±5.0a,b,c 
Myoglobin (17,200Da)  68.2±6.7  64.1±6.2a  70.7±5.9b  81.8±5.3a,b,c 
Prolactin (23,000Da)  65.0±7.3  62.2±6.4  61.1±9.3  74.4±7.7a,b,c 
α1-Microglobulin (33,000Da)  17.3±5.8  15.8±5.1  13.5±5.4  23.5±5.9a,b,c 
α1-Acid glycoprotein (41,000Da)  3.8±7.5  6.4±5.5  3.7±6.3  11.5±5.6a,b,c 
a

p<0.01 relative to Sureflux-HD.

b

p<0.01 relative to Sureflux-HDF.

c

p<0.01 relative to Solacea-HD.

Fig. 2.
(0.13MB).

Variations in percentage of urea and creatinine reduction by dialyser, n=16, ANOVA for repeated data.

Fig. 3.
(0.19MB).

Variations in the percentage of β2-microglobulin, myoglobin and prolactin reduction by dialyser, n=16, ANOVA for repeated data.

Fig. 4.
(0.13MB).

Variations in the percentage of α1-microglobulin and α1-acid glycoprotein reduction by dialyser, n=16, ANOVA for repeated data.

Small molecules

The clearance of urea and creatinine was similar in the Solacea 19H dialyser and Sureflux 19UX in (Fig. 2).

Large molecules

If the molecular size of solutes to be cleared is increased, there are differences observed between both filters and between the dialysis modalities. Above 30kDa, although differences between filters both in HD and in HDF are observed, the percentage reduction of these molecules is less than 25%. It therefore seems that these dialysers’ cut-off limit has already been reached. The Solacea 19H dialyser, mainly with on-line HDF, presented the greatest clearance of large molecules.

a) β2-m (11,800Da): In HD, the Solacea 19H removed 6.3% more than the Sureflux 19UX (p<0.01). In on-line HDF, the Solacea 19H removed 29% more than the Sureflux 19UX (p<0.01). Comparison of on-line HDF and HD with the same dialyser, shows that the Sureflux 19UX reduction percentage worsened by 7.3% compared to HD (p<0.01), while Solacea 19H's was 12.5% higher than with HD (p<0.01) (Fig. 3).

b) Myoglobin (17,200Da): Removal of myoglobin by the Solacea 19H dialyser is similar to that of the Sureflux 19UX dialyser in HD. However, in on-line HDF, the Solacea 19H removed 27.7% more than the Sureflux 19UX (p<0.01). Again, the Sureflux 19UX reduction percentage worsened by 6.0% as compared to HD (p<0.05), while the Solacea 19H was 15.8% higher in on-line HDF than in HD (p<0.01) (Fig. 3).

c) Prolactin (23,000Da): The Solacea 19H dialyser removes prolactin in a similar manner as the Sureflux 19UX dialyser in HD. However, in on-line HDF, the Solacea 19H removed 19.5% more than the Sureflux 19UX (p<0.01). Comparison of on-line HDF with HD with the Sureflux 19UX, shows that its reduction percentage worsened by 4.3% (NS), while with the Solacea 19H it was 21.7% higher than HD (p<0.01) (Fig. 3).

d) α1-microglobulin (33,000Da): Removal of α1-microglobulin by the Solacea 19H dialyser is similar to the Sureflux 19UX dialyser in HD. However, in on-line HDF, the Solacea 19H removed 49% more than the Sureflux 19UX (p<0.01). With Sureflux 19UX the percentage reduction was also reduced by 8.6% (p<0.01) while with the Solacea 19H it was 73% higher than in HD (p<0.01) (Fig. 4).

e) α1-acid glycoprotein (41,000Da): Removal of α1-acid glycoprotein by Solacea 19H dialyser and Sureflux 19UX dialyser in HD, are similar and both have a very limited clearance, less than 5%. However, in on-line HDF, the Solacea 19H removed almost twice as much as the Sureflux 19UX (p<0.01). Comparison of Sureflux 19UX on-line HDF to HD, shows that the percent reduction did not change, while with the Solacea 19H, it tripled (p<0.01) (Fig. 4).

It is worth to mention that that the Sureflux 19UX dialyser does not improve the clearance of large molecules with on-line HDF. In fact, it is inferior to HD (between 10,000 and 25,000Da). This performance is rather unusual and it may be assumed that even achieving 15–20l of convective volume, the clearance capacity of the pores is modified.

Albumin loss in dialysate

As in the native kidney, it is desirable a minimal loss of albumin during the dialysis sessions. The percent reduction of albumin in the blood was 6.4% with Sureflux 19UX in HD, 4.2% with Solacea 19H in HD, 5.6% with Sureflux 19UX in on-line HDF and 8.1% with Solacea 19H in HDF.

The amount of albumin eliminated in the dialysis fluid was 1.19g with Sureflux 19UX in HD, 0.84g with Solacea 19H in HD, 1.77g with Sureflux 19UX in on-line HDF and 1.71g with Solacea 19H in on-line HDF. In both HDF treatments albumin loss is significantly greater than in the other two treatments in HD (Fig. 5).

Fig. 5.
(0.05MB).

Albumin loss in dialysis fluid by dialyser and treatment modality studied.

Discussion

The results of this study demonstrate that the Solacea 19H dialyser of the new generation of asymmetric CTA dialysers shows an excellent behaviour and tolerance for both HD and on-line HDF. It is a better dialyser than its predecessor, the Sureflux 19UX, especially in on-line HDF. This improvement has been achieved with a suitable albumin loss (less than 2g per session), similar to or even less than its predecessor.

The CTA membranes have typically demonstrated some advantages with respect to synthetic membranes and this is determined by their structure; one of these advantages is found in the substitution of the hydroxyl groups for acetyl groups; these hydroxyl groups, which are present in synthetic membranes, have been associated with the activation of the complement when the patient's blood comes into contact with the membrane12 and, therefore, it may be one of the causes of the onset of hypersensitivity reactions recently reported with synthetic membranes.9,10 Another of their differentiating characteristics is that they are hydrophilic membranes. This means that they do not require the addition of hydrophiliating elements, which are another possible cause of hypersensitivity reactions.13 Additionally, CTA membranes are characterised by the presentation of a low electric charge: this will be very important in a membrane's absorption capacity because low electric charges in membranes cause a low absorption capacity,14 and this will influence the antithrombotic properties described relative to these membranes.15 Together with these properties, it is known that a low electric charge in the membrane can improve the clearance of inorganic phosphorus and the lipid profile.16 Another difference is that these membranes are bisphenol A- and polyvinylpyrrolidone-free. These are products which are present in other synthetic membranes, and which have been described as being associated with an increase in inflammation and oxidative stress.17

One of the classic limitations of cellulosic dialysers has been the low biocompatibility.18,19 Later, the changes made in their structure with the substitution of hydroxyl groups by acetyl groups have substantially improved these membranes’ biocompatibility. A clear example is the CTA modifications, which demonstrate significant improvement in their biocompatibility profiles with respect to conventional cellulosic dialysers.13 The membranes of the new asymmetric CTA generation with the modifications present in their structure could improve this profile even more compared to conventional CTAs.20

This new generation of asymmetric CTA dialysers marketed in Japan (and recently marketed in Spain) differentiates itself from the previous one in that the membrane has an asymmetric structure, an increase in capillary fibre density, and that it nearly doubles the ultrafiltration coefficient.20 This increase in membrane thickness, still less than synthetic dialysers, decreases diffusion slightly, but also allows for larger pores to be supported, increases their hydraulic permeability and, therefore, increases convective transport. Exactly as has been seen in this study, the clearance of small and large molecules in HD with asymmetric CTA is similar to that of the CTA generation, which is why a change of dialyser that continues with the HD modality would not be particularly justified. Notwithstanding, the new asymmetric CTA dialyser reached a much higher substitution volume than its CTA predecessor, with a suitable convective volume complying with current recommendations. And, more importantly, this increase in convective volume meant an increase in the clearance of all solutes analysed, especially solutes with high molecular weights. These benefits make this dialyser worth recommending both for HD use as well as its increased benefits for on-line HDF.

In corroboration with the previous study,7 the conventional CTA dialyser, Sureflux 19UX, did not provide a sufficient convective volume and, more surprisingly, this convective volume did not help to improve clearance, but instead diminished it in the case of large molecules. This is truly uncommon, since the majority of dialysers increase their clearance capacity when high convective volume is added. It seems reasonable that this dialyser should be prescribed only for HD treatments.

It is known that one of the limiting factors of dialysers, especially in on-line HDF, is the loss of albumin. In the recent analysis conducted by Potier et al.8 of 19 membranes used in on-line HDF, it is stated that some of them have a greater albumin loss than recommended, and, therefore, that they should not be used in techniques with elevated convective transport. Our study confirms the low albumin loss of these asymmetric CTA dialysers. This fact, together with its improvement in terms of mid-sized molecule clearance and its biocompatibility profile, would allow them to be used for on-line HDF.

Post-dilution on-line HDF has demonstrated to produce an increase in survival rates1 and, subsequently, various meta-analyses confirmed a reduction in cardiovascular and overall mortality.2,3 Synthetic membranes with high permeability and low albumin loss, such as polysulfones and polyethersulfones, have been used up until now to obtain a suitable convective volume and correct molecule clearance, with no evident clinical problems. In recent years, cases of hyperreactivity associated with this type of membrane have been reported.9,10 CTA membranes have been used as an alternative for dialysis in these patients and to prevent the onset of sensitivity. Up to now, it was not known whether the new asymmetric CTA filters were suitable to perform techniques with high convective transport. The data from this study show that this new generation of membranes achieve the recommended convective volume, as well as small and large molecule clearance.

We conclude that the new generation CTA dialyser, Solacea 19H, has exceeded its predecessor in all markers analysed, and would be indicated for both HD and, even more so, for on-line HDF. The prescription of the Sureflux 19UX dialyser should be limited to use in HD, because, even though on-line HDF allows for a convective volume of between 15 and 25 l, it was not associated with greater clearance of small or large molecules.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Acknowledgements

We would like to give thanks to all patients who have participated, as well as all personnel from the Dialysis Department of the Hospital Clínic de Barcelona, for their collaboration in this study and their enthusiasm.

References
[1]
F. Maduell, F. Moreso, M. Pons, R. Ramos, J. Mora-Macià, J. Carreras
High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients
J Am Soc Nephrol, 24 (2013), pp. 487-497 http://dx.doi.org/10.1681/ASN.2012080875
[2]
I.M. Mostovaya, P.J. Blankestijn, M.L. Bots, A. Covic, A. Davenport, M.P. Grooteman, EUDIAL Group
Clinical evidence on hemodiafiltration: a systematic review and a meta-analysis
Semin Dial, 27 (2014), pp. 119-127
[3]
I. Nistor, S.C. Palmer, J.C. Craig, V. Saglimbene, M. Vecchio, A. Covic
Convective versus diffusive dialysis therapies for chronic kidney failure: an updated systematic review of randomized controlled trials
Am J Kidney Dis, 63 (2014), pp. 954-967 http://dx.doi.org/10.1053/j.ajkd.2013.12.004
[4]
M.P.C. Grooteman, M.A. van den Dorpel, M.L. Bots, E.L. Penne, N.C. van der Weerd, A.H. Mazairac
Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes
J Am Soc Nephrol, 23 (2012), pp. 1087-1096 http://dx.doi.org/10.1681/ASN.2011121140
[5]
E. Ok, G. Asci, H. Toz, E.S. Ok, F. Kircelli, M. Yilmaz
Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF study
Nephrol Dial Transplant, 28 (2013), pp. 192-202 http://dx.doi.org/10.1093/ndt/gfs407
[6]
B. Canaud, S.K. Bowry
Emerging clinical evidence on online hemodiafiltration: does volume of ultrafiltration matter?
Blood Purif, 35 (2013), pp. 55-62 http://dx.doi.org/10.1159/000346371
[7]
F. Maduell, V. Navarro, J. Hernández-Jaras, C. Calvo
Comparación de dializadores en hemodiafiltración en línea
Nefrología, 20 (2000), pp. 269-276
[8]
J. Potier, G. Queffeulou, J. Bouet
Are all dialyzers compatible with the convective volumes suggested for postdilution online hemodiafiltration?
Int J Artif Organs, 39 (2016), pp. 460-470 http://dx.doi.org/10.5301/ijao.5000525
[9]
R.J. Sánchez-Villanueva, E. González, S. Quirce, R. Díaz, L. Álvarez, D. Menéndez
Reacciones de hipersensibilidad a membranas sintéticas de hemodiálisis
[10]
M.A. Alvarez-de Lara, A. Martín-Malo
Hypersensitivity reactions to synthetic haemodialysis membranes an emerging issue?
[11]
J. Bergström, B. Wehle
No change in corrected β2-microglobulin concentration after cuprophane haemodialysis
Lancet, 1 (1987), pp. 628-629
[12]
N.A. Hoenich, C. Woffindin, J.N. Mathews
Biocompatibility of membranes used in the treatment of renal failure
Biomaterials, 16 (1995), pp. 587-592
[13]
T. Sunohara, T. Masuda
Cellulose triacetate as a high-performance membrane
Contrib Nephrol, 173 (2011), pp. 156-163 http://dx.doi.org/10.1159/000329055
[14]
J.L. Renaux, M. Thomas, T. Crost, N. Loughraieb, G. Vantard
Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH
[15]
J. Chanard, S. Lavaud, C. Randoux, P. Rieu
New insights in dialysis membrane biocompatibility: relevance of adsorption properties and heparin binding
Nephrol Dial Transplant, 18 (2003), pp. 252-257
[16]
Y. Otsubo, T. Tabe, K. Takenouchi, M. Toyama, Y. Uruta, Y. Uchida
Lipid metabolism in dialyzed patients treated with CTA membrane. In cellulose triacetate
Milan Witchting, (1994), pp. 161-170
[17]
E. Bosch-Panadero, S. Mas, D. Sanchez-Ospina, V. Camarero, M.V. Pérez-Gómez, I. Saez-Calero
The choice of hemodialysis membrane affects bisphenol A. Levels in blood
J Am Soc Nephrol, 27 (2016), pp. 1566-1574 http://dx.doi.org/10.1681/ASN.2015030312
[18]
J. Carracedo, R. Ramírez, A. Martín-Malo, M. Rodríguez, P. Aljama
Nonbiocompatible hemodialysis membranes induce apoptosis in mononuclear cells: the role of G-proteins
J Am Soc Nephrol, 9 (1998), pp. 46-53
[19]
A. Martín-Malo, J. Carracedo, R. Ramírez, A. Rodriguez-Benot, S. Soriano, M. Rodriguez
Effect of uremia and dialysis modality on mononuclear cell apoptosis
J Am Soc Nephrol, 11 (2000), pp. 936-942
[20]
T. Sunohara, T. Masuda
Fundamental characteristics of the newly developed ATA™ Membrane Dialyzer
Contrib Nephrol, 189 (2017), pp. 215-221 http://dx.doi.org/10.1159/000451044

Please cite this article as: Maduell F, Ojeda R, Arias-Guillén M, Fontseré N, Vera M, Rodas L, et al. Una nueva generación de triacetato de celulosa adecuado para hemodiafiltración on-line. Nefrologia. 2018;38:161–168.

Copyright © 2017. Sociedad Española de Nefrología
Idiomas
Nefrología (English Edition)

Subscribe to our Newsletter

Article options
Tools
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?